Dugan Sara E, Fuller Matthew A
Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10000 Brecksville Rd., Brecksville, OH 44141, USA.
Ann Pharmacother. 2004 Dec;38(12):2078-85. doi: 10.1345/aph.1E084. Epub 2004 Nov 2.
To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of duloxetine for the treatment of major depressive disorder (MDD).
Searches using MEDLINE and PsycINFO were conducted (1966 to November 2003).
All duloxetine MDD information gathered was considered. Articles containing comprehensive information regarding duloxetine use for MDD were evaluated.
Duloxetine is a serotonin-norepinephrine reuptake inhibitor being considered for treatment of MDD and stress urinary incontinence. While approved dosing ranges have not yet been determined, studies support the efficacy and safety of 40-60 mg twice daily for the treatment of acute MDD. Adverse effects have been of mild to moderate severity and are considered to be transient. Cardiovascular effects (increased heart rate or blood pressure), while present, do not appear to be clinically significant. Overall, duloxetine appears to be well tolerated.
Duloxetine is a safe and effective antidepressant. Approval of this agent provides another treatment option for the management of MDD.
综述度洛西汀治疗重度抑郁症（MDD）的药理学、药代动力学、临床疗效及安全性。
检索MEDLINE和PsycINFO数据库（1966年至2003年11月）。
纳入所有收集到的度洛西汀治疗MDD的信息。对包含度洛西汀治疗MDD全面信息的文章进行评估。
度洛西汀是一种5-羟色胺-去甲肾上腺素再摄取抑制剂，正被考虑用于治疗MDD和压力性尿失禁。虽然尚未确定批准的给药范围，但研究支持每日两次40-60mg治疗急性MDD的疗效和安全性。不良反应为轻至中度，且被认为是短暂的。心血管效应（心率或血压升高）虽然存在，但似乎无临床意义。总体而言，度洛西汀耐受性良好。
度洛西汀是一种安全有效的抗抑郁药。该药物的获批为MDD的治疗提供了另一种选择。
